Wilkinson, Adam C. http://orcid.org/0000-0001-7406-0151
Dever, Daniel P. http://orcid.org/0000-0001-5966-4803
Baik, Ron
Camarena, Joab http://orcid.org/0000-0002-3102-5820
Hsu, Ian
Charlesworth, Carsten T.
Morita, Chika http://orcid.org/0000-0003-1317-685X
Nakauchi, Hiromitsu http://orcid.org/0000-0002-9841-6973
Porteus, Matthew H. http://orcid.org/0000-0002-3850-4648
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K99HL150218, R01HL135607, R01HL147124)
Leukemia and Lymphoma Society (3385-19)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK116944)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
California Institute for Regenerative Medicine (LA1_C12-06917)
Doris Duke Charitable Foundation (2019112)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI097320, R01AI120766)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 5 October 2020
Accepted: 23 December 2020
First Online: 29 January 2021
Competing interests
: H.N. is a co-founder and shareholder in ReproCELL, Megakaryon, and Century Therapeutics. M.H.P. has equity and serves on the scientific advisory board of CRISPR Therapeutics and Allogene Therapeutics. However, none of these companies had input into the design, execution, interpretation, or publication of the work in this manuscript. All other authors do not declare any competing interests.